Bevacizumab in ovarian cancer: time-dependent changes in risk of progression https://www.medrxiv.org/content/10.1101/2023.02.14.23285833
QOTO: Question Others to Teach Ourselves An inclusive, Academic Freedom, instance All cultures welcome. Hate speech and harassment strictly forbidden.